Psychiatric polygenic risk scores: Experience, hope for utility, and concerns among child and adolescent psychiatrists.

Autor: Merner AR; Center for Bioethics, Harvard Medical School, Boston, MA 02115, United States., Trotter PM; Center for Medical Ethics & Health Policy at Baylor College of Medicine, United States., Ginn LA; Center for Medical Ethics & Health Policy at Baylor College of Medicine, United States; Department of Biosciences, Rice University, Houston, Texas, United States., Bach J; University of Pennsylvania Law School, Philadelphia, Pennsylvania, United States., Freedberg KJ; Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States., Soda T; Department of Psychiatry, University of Florida, Gainesville, Florida, United States; Center for Autism and Neurodevelopment, University of Florida, Gainesville, Florida, United States., Storch EA; Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, Texas, United States., Pereira S; Center for Medical Ethics & Health Policy at Baylor College of Medicine, United States., Lázaro-Muñoz G; Center for Bioethics, Harvard Medical School, Boston, MA 02115, United States; Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, United States. Electronic address: glazaro@hms.harvard.edu.
Jazyk: angličtina
Zdroj: Psychiatry research [Psychiatry Res] 2024 Sep; Vol. 339, pp. 116080. Date of Electronic Publication: 2024 Jul 07.
DOI: 10.1016/j.psychres.2024.116080
Abstrakt: Recent advances in psychiatric genetics have enabled the use of polygenic risk scores (PRS) to estimate genetic risk for psychiatric disorders. However, the potential use of PRS in child and adolescent psychiatry has raised concerns. This study provides an in-depth examination of attitudes among child and adolescent psychiatrists (CAP) regarding the use of PRS in psychiatry. We conducted semi-structured interviews with U.S.-based CAP (n = 29) who possess expertise in genetics. The majority of CAP indicated that PRS have limited clinical utility in their current form and are not ready for clinical implementation. Most clinicians stated that nothing would motivate them to generate PRS at present; however, some exceptions were noted (e.g., parent/family request). Clinicians spoke to challenges related to ordering, interpreting, and explaining PRS to patients and families. CAP raised concerns regarding the potential for this information to be misinterpreted or misused by patients, families, clinicians, and outside entities such as insurance companies. Finally, some CAP noted that PRS may lead to increased stigmatization of psychiatric disorders, and at the extreme, could be used to support eugenics. As PRS testing increases, it will be critical to examine CAP and other stakeholders' views to ensure responsible implementation of this technology.
Competing Interests: Declaration of competing interest Dr. Merner reports no financial relationships with commercial interests. Ms. Trotter reports no financial relationships with commercial interests. Ms. Ginn reports no financial relationships with commercial interests. Mr. Bach reports no financial relationships with commercial interests. Dr. Freedenberg reports no relationships with commercial interests. Dr. Soda receives grant support from NIH. Dr. Merner reports no financial relationships with commercial interests. Dr. Storch was a consultant for Biohaven and Brainsway in the past 12 months. He receives grant support from NIH, International OCD Foundation, and Ream Foundation. He owns stock valued under $5000 in Nview. He receives book royalties from Elsevier, Springer, Oxford, Guilford, American Psychological Association, Lawrence Erlbaum, and Jessica Kingsley. Dr. Pereira receives grant support from NIH. Dr. Lázaro-Muñoz receives grant support from NIH.
(Copyright © 2024. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: